Neil Warma says ProMIS designed PMN310 to bind only toxic oligomer species of amyloid beta, avoiding plaque. He notes plaque-clearing drugs can cause ARIA swelling/bleeding, and plaque removal alone doesn't stop cognitive decline. He says the antibody must avoid plaque while hitting upstream oligomers. This selectivity is the core best-in-class bet.
Warma says drugs can completely eliminate plaque while patients continue to decline, and plaque-binding drugs carry ARIA risk. He argues the industry now sees toxic oligomers as the subspecies driving cognitive decline, making plaque a less relevant or insufficient target. That shift explains why ProMIS is not chasing plaque clearance as its main endpoint.
Warma says ProMIS chose a 140-patient, 12-month phase 1b instead of a quick 30-patient biomarker study. By checking safety, target engagement, dose, and clinical signal, they hope to move straight into a registration phase 3, saving years and cost. He says the longer, costlier design was deliberate because short biomarker studies left partners unsure.
Warma says when ProMIS proposed the larger phase 1b, investors were more interested than in a quick-and-dirty study because they saw the path to skipping phase 2. Pharma partners also responded well to the comprehensive design. He notes the tradeoff is a longer public-company news wait and higher cost, but the pros outweighed cons.
ProMIS reported six-month blinded interim data with zero ARIA-E, background ARIA-H similar to placebo, and declines in p-tau217 and MTBR243. Warma stresses they did not look at clinical outcomes, so the unblinded Q1 read is still needed to show actual benefit. He says the interim met or overachieved expectations on safety and target engagement.
Warma lists the prerequisites for a registration study: deliver the drug safely, cross the blood-brain barrier to engage target, show biomarker movement, identify a dose, and demonstrate clinical benefit. ProMIS has fast-track designation and plans an end-of-phase-2 FDA meeting. He says these are the boxes that must be checked before starting phase 3.
Warma says CAR-T can only target extracellular antigens, limiting it to less than 3% of cancer patients. Mongoose Bio's TCR T-cell approach, from Cassian Yi at MD Anderson, goes after novel intracellular targets expressed on solid tumors. He says this opens treatment to patients who currently lack CAR-T options.
Warma says immuno-oncology therapies often shrink tumors, but cancers relapse after four to six months because T cells become exhausted. Mongoose's platform reprograms T cells to persist for years and keep cancer in remission. He says solving persistence is as important as finding novel targets for solid tumors.
Warma says outstanding science is not enough; emerging companies need people who have executed manufacturing, preclinical-to-clinical transitions, and regulatory work multiple times. He warns against teams learning these critical functions on the go. He also cites culture, leadership, and global partnerships as consistent ingredients for success.
Warma argues that leveraging technology, capital, and people across the US, China, South Korea, and Japan creates more shareholder value while keeping drugs affordable globally. He says this global thinking is often missed by US companies. He applies that lens at ProMIS and Mongoose when considering collaborations and capital.
Warma says quitting a comfortable Novartis career to start his own company in New York was pivotal. He had to raise money, hire people, and manage for himself, which brought out a different element and led to later CEO roles. He frames his career as a series of opportunities rather than a formal plan.
